Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis

NCT05442190 is registered in ClinicalTrials.gov with Soligenix as lead sponsor.

NCT NCT05442190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05442190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis
Lead sponsor
Soligenix
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2022
Completion date
November 17, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriasis, psoriasis vulgaris